IntelliCyt Corp., a provider of innovative high throughput cell and bead-based screening products for drug discovery and life science research, introduced its new High Throughput Flow Cytometry – HTFC Screening System.
Designed to enable large scale, high throughput, high content screening, IntelliCyt’s new HTFC Screening System takes a revolutionary approach to cell-based screening by integrating the company’s proprietary HyperCyt technology and flow cytometry – the most sensitive technology for measuring fluorescent markers on cells in suspension – with HyperCytPRO, IntelliCyt’s advanced server-based informatics platform. The result is a powerful yet simple screening system that enables researchers to cost effectively perform broader experiments with more controls and replicates, screen more compounds, and analyze data in ways never before possible with conventional flow cytometry.
“The HTFC Screening System represents a significant breakthrough in high content screening because it broadens the types of cells and multiplexed assays that can be used for testing compounds in drug discovery research,” said Terry Dunlay, IntelliCyt president and CEO. “By coupling our high-throughput sampler with the large dynamic range and multiplexing capability of flow cytometry-based detectors, the HTFC Screening System provides scientists with powerful advantages over other currently available technologies.”
Using the HTFC Screening System, researchers can analyze multiparameter cell populations or multiplexed bead suspensions in 96- and 384-well microplates at rates up to 40 wells per minute, capturing data on thousands of cells per second. Because the HTFC Screening system can accommodate very small specimens, sample and reagent requirements are reduced by 50 to 90 percent, resulting in significant cost savings. The heightened sensitivity and multicolor capabilities of the flow cytometer detection system also enable additional applications, including antibody screening, cytotoxicity studies and biomarker analysis.
“We are grateful to many of our early customers, who have been using earlier versions of our HyperCyt Systems at major pharmaceutical companies, biotechnology companies, and leading academic research organizations. Their feedback led to many of the new powerful and user-friendly features in the HTFC Screening System,” said Dunlay.
This article was published in Drug Discovery & Development magazine: Vol. 13, No. 4, May 2010, p. 9.